Voyager Therapeutics Inc (VYGR)

NASD · Healthcare · Biotechnology · USA

Voyager Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases including Alzheimer's disease, Friedreich's ataxia, and Parkinson's disease. The company's pipeline includes wholly-owned tau-targeting programs and collaborative programs with partners such as Neurocrine and Novartis, leveraging its TRACER platform for brain penetration through intravenous dosing.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Voyager Therapeutics Inc stock.

Our verdict on VYGR

Undervalued: intrinsic value $2.35 per share, market price $1.52, margin of safety 35.4% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $2.35; the price of $1.52 is 35% below that value.

ETFs with the most weight in VYGR

17 more funds hold it; the full list is part of the paid plan.

More on VYGR

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than VYGR in Biotechnology

10 more in this industry show a wider margin of safety.

Is VYGR undervalued or overvalued?

VYGR is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $2.35; the price of $1.52 is 35% below that value.

What is the intrinsic value of VYGR?

$2.35 per share (as of the 2026-11-17 close), against a market price of $1.52. That is a margin of safety of 35.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.